Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

881. Postmenopausal hormone replacement therapy and cardiovascular disease

Postmenopausal hormone replacement therapy and cardiovascular disease Postmenopausal hormone replacement therapy and cardiovascular disease Postmenopausal hormone replacement therapy and cardiovascular disease Humphrey L L, Takano L M, Chan B K Authors' objectives The objective was to evaluate the association between hormone replacement therapy (HRT) and the primary prevention of cardiovascular disease (CVD). Searching MEDLINE was searched from 1966 to 2000 and the Cochrane Library was reviewed (...) that results from large RCTs are needed. In addition, further research should investigate whether particular subgroups or women are at particular risk, and look at the effects of HRT on non-Caucasian women Funding Agency for Healthcare Research and Quality, contract number 290-97-0018. Bibliographic details Humphrey L L, Takano L M, Chan B K. Postmenopausal hormone replacement therapy and cardiovascular disease. Rockville, MD, USA: Agency for Healthcare Research and Quality. Systematic Evidence Review; 10

2002 DARE.

882. Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality

Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality Boltri J M, Akerson M R, Vogel R L Authors' objectives To assess whether aspirin reduces all-cause mortality in low-risk patients. Searching MEDLINE (...) between 1 and 15 aspirin tablets per week (the exact dosage was not specified) versus no aspirin. Participants included in the review Participants at low risk of cardiovascular disease were eligible for inclusion. Low risk was defined as having no more than one of the following risk factors: hypertension, low high-density lipoprotein cholesterol, high low-density lipoprotein cholesterol, family history of premature coronary heart disease, smoking, diabetes or advancing age (men greater than 45 years

2002 DARE.

883. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review

Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review Asplund K Authors' objectives To assess whether antioxidant vitamins, in regular food or as food supplements, protect against myocardial infarction or stroke. In practice, the author assessed the effect of antioxidant vitamins (...) Cardiovascular disease, including ischaemic heart disease deaths or events, or stroke, was assessed. Adverse events were also reported. The outcomes were not clearly defined, and all-cause mortality was not considered. How were decisions on the relevance of primary studies made? The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection. Assessment of study quality The author states that the validity of the studies was assessed against strict

2002 DARE.

884. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project

Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.

885. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study

Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study Marshall T, Rouse A Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two groups of guidelines for the primary prevention of cardiovascular disease in people aged 30 to 74 years were studied. These were guidelines based on the joint British recommendations (JBR

2002 NHS Economic Evaluation Database.

886. Impact of high-normal blood pressure on the risk of cardiovascular disease. (Abstract)

Impact of high-normal blood pressure on the risk of cardiovascular disease. Information is limited regarding the absolute and relative risk of cardiovascular disease in persons with high-normal blood pressure (systolic pressure of 130 to 139 mm Hg, diastolic pressure of 85 to 89 mm Hg, or both).We investigated the association between blood-pressure category at base line and the incidence of cardiovascular disease on follow-up among 6859 participants in the Framingham Heart Study who were (...) initially free of hypertension and cardiovascular disease.A stepwise increase in cardiovascular event rates was noted in persons with higher baseline blood-pressure categories. The 10-year cumulative incidence of cardiovascular disease in subjects 35 to 64 years of age who had high-normal blood pressure was 4 percent (95 percent confidence interval, 2 to 5 percent) for women and 8 percent (95 percent confidence interval, 6 to 10 percent) for men; in older subjects (those 65 to 90 years old

2001 NEJM

887. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. (Abstract)

Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. Cost-sharing in US prescription drug coverage plans for elderly persons varies widely. Evaluation of prescription drug use among elderly persons by type of health insurance could provide useful information for designing a Medicare drug program.To determine use of effective cardiovascular drugs among elderly persons with coronary heart disease (CHD) by type of health

2001 JAMA

888. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). (Abstract)

Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Little is known about the rates of cardiovascular disease (CVD), atherosclerosis, and their risk factors among Canada's Aboriginal people. To establish the relative prevalence of risk factors, atherosclerosis, and CVD, we undertook a population-based study among people of Aboriginal and European ancestry in Canada.We

2001 Lancet

889. Nutrition and physical activity interventions to reduce cardiovascular disease risk in health care settings: a quantitative review with a focus on women

Nutrition and physical activity interventions to reduce cardiovascular disease risk in health care settings: a quantitative review with a focus on women Nutrition and physical activity interventions to reduce cardiovascular disease risk in health care settings: a quantitative review with a focus on women Nutrition and physical activity interventions to reduce cardiovascular disease risk in health care settings: a quantitative review with a focus on women Wilcox S, Parra-Medina D, Thompson (...) -Robinson M, Will J Authors' objectives To evaluate the impact of diet and physical activity interventions delivered in health care settings on cardiovascular disease risk factors in women. Searching MEDLINE, CINAHL, Current Contents and PsycINFO were searched from 1980 to 2000. Search terms pertinent for diet, exercise, counselling, women, and African American women were used and are listed in the review article. The bibliographies of retrieved original and review articles were also searched. Study

2001 DARE.

890. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus

TC, et al. Early or late deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med 1995;122:856-66. These additional published commentaries may also be of interest. Ganda OM. Review: interventions that lower cholesterol concentrations or blood pressure in diabetic patients prevent cardiovascular disease. Evid Based Med 2002;7:107. Ganda OM. Review: interventions that lower cholesterol concentrations or blood pressure in diabetic patients prevent (...) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus Huang E S, Meigs J B, Singer D E Authors' objectives To quantify the cardiovascular benefit of lowering cholesterol, blood-pressure and glucose levels in patients with type 2 diabetes

2001 DARE.

891. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?

How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Grover S A, Coupal L, Zowall H, Alexander C M, Weiss T W, Gomes D R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin to treat dyslipidaemia, and to reduce the risk of myocardial infarction in patients with diabetes or with cardiovascular disease (CVD). Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

892. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron (Abstract)

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron Aspirin lowers risks of death and myocardial infarction in patients with acute coronary syndromes. Intravenous glycoprotein IIb/IIIa receptor antagonists further reduce the rates of ischaemic events in these patients, but the efficacy of long (...) -term oral glycoprotein IIb/IIIa receptor blockade has not been established. We tested whether the oral glycoprotein IIb/IIIa receptor antagonist sibrafiban would prevent more cardiovascular events than aspirin, when given within 7 days of, and sustained for 90 days after, an acute coronary syndrome event.9233 patients who had stabilised after an acute coronary syndrome event were randomly assigned aspirin (80 mg orally twice daily) or low-dose or high-dose sibrafiban. Sibrafiban doses (3.0 mg, 4.5

2000 Lancet Controlled trial quality: predicted high

893. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. (Abstract)

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Excess cardiovascular mortality has been documented in chronic haemodialysis patients. Oxidative stress is greater in haemodialysis patients with prevalent cardiovascular disease than in those without, suggesting a role for oxidative stress in excess cardiovascular disease in haemodialysis. We investigated the effect of high-dose vitamin E supplementation (...) on cardiovascular disease outcomes in haemodialysis patients with pre-existing cardiovascular disease.Haemodialysis patients with pre-existing cardiovascular disease (n=196) aged 40-75 years at baseline from six dialysis centres were enrolled and randomised to receive 800 IU/day vitamin E or matching placebo. Patients were followed for a median 519 days. The primary endpoint was a composite variable consisting of: myocardial infarction (fatal and non-fatal), ischaemic stroke, peripheral vascular disease

2000 Lancet Controlled trial quality: predicted high

894. Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects

Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects Agency for Healthcare Research and Quality (AHRQ) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Agency for Healthcare Research and Quality (AHRQ). Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 20. 2000 Authors' objectives This report addresses three areas: 1. Effects on cardiovascular-related disease and factors

2000 Health Technology Assessment (HTA) Database.

895. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors

Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors Ketola E, Sipila R, Makela M Authors' objectives To assess the effectiveness of lifestyle interventions in reducing cardiovascular disease risk factors, morbidity and mortality among (...) , exercise, smoking cessation, and alcohol intake reduction. Studies combining CVD drug treatment with lifestyle interventions were accepted only if the drugs were not the primary intervention. Participants included in the review Adults of working-age who are at risk of cardiovascular disease (CVD) (i.e. primary prevention) or who have experienced any CVD event such as coronary heart disease, hypertension, stroke, congestive heart failure, rhythm disturbances etc. (i.e. secondary prevention). Studies

2000 DARE.

896. Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects

-distilled, enteric-coated beta-cyclodextrin-bound garlic oil preparation; or garlic combined with other substances, such as fish oil, ginkgo, soya or hawthorn. Participants included in the review The participants eligible and included in the review were adults or children with or without dyslipidemia, hypertension or diabetes; those at average or high risk for cardiovascular disease; adults without cancer risk factors, precancerous conditions or malignancy; adults with cancer risk factors (...) , but no precancerous conditions or malignancy; and adults with cancer. Outcomes assessed in the review For questions relating to cardiovascular disease, physiological and clinical outcomes were examined. The physiological outcomes included lipids, blood-pressure, insulin sensitivity/glucose or glycosylated haemoglobin, or antithrombotic activity. The clinical outcomes included cardiovascular morbidity or mortality (such as stroke, myocardial infarction, angina incidence or severity), peripheral vascular disease

2000 DARE.

897. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease Lowensteyn I, Coupal L, Zowall H, Grover S A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Exercise training to improve cardiovascular disease (CVD) risk factors was investigated. Exercise training was defined as aerobic exercise performed at least 3 times per week for 30 minutes per session, within 65 to 85% of an individual's maximum heart rate. Type of intervention Primary

2000 NHS Economic Evaluation Database.

898. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease

Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease Vorchheimer D A, Badimon J J, Fuster V Authors' objectives To review the effectiveness of platelet glycoprotein IIb/IIIa receptors in cardiovascular disease. Searching The authors searched the MEDLINE database (1993-1998) for English language publications using (...) in order to make determinations about the efficacy of administration in different treatment situations. Bibliographic details Vorchheimer D A, Badimon J J, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999; 281(15): 1407-1414 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants /therapeutic use; Cardiovascular Diseases /blood /drug therapy /therapy; Cerebral

1999 DARE.

899. A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment- keeping in the treatment of cardiovascular disease Full Text available with Trip Pro

A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment- keeping in the treatment of cardiovascular disease A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment- keeping in the treatment of cardiovascular disease A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment- keeping (...) in the treatment of cardiovascular disease Newell S A, Bowman J A, Cockburn J D Authors' objectives The authors' stated objectives were to critically review the literature regarding the interventions to improve cardiovascular patients' compliance with medication taking, obtaining medication refills, or appointment keeping. What the authors appeared to study were these interventions in relation to the primary and secondary prevention of cardiovascular disease. Searching MEDLINE, HealthPLAN and PsycLIT databases

1999 DARE.

900. Effects of the National Cholesterol Education Program's step I and step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis

Effects of the National Cholesterol Education Program's step I and step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis Effects of the National Cholesterol Education Program's step I and step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis Effects of the National Cholesterol Education Program's step I and step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis Yu-Poth S, Zhao (...) G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton P M Authors' objectives To evaluate the effects of the National Cholesterol Education Program's Step I and Step II dietary interventions on major cardiovascular disease risk factors. Searching MEDLINE (1981 to 1997) and the references in the papers identified were searched. Study selection Study designs of evaluations included in the review The a-priori inclusion criteria with regards to study design was not reported. Included studies were

1999 DARE.